Skip to Content Facebook Feature Image

THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA

Business

THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA
Business

Business

THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA

2025-05-09 10:00 Last Updated At:10:15

BANGKOK, May 9, 2025 /PRNewswire/ -- A professor from Chulalongkorn University's Faculty of Science has developed a skincare formula using microbiome and 4P-biotics technology, resulting in a serum and sunscreen lotion under the brand THANARA. These products help balance the microbiome on facial skin, promoting a healthy, youthful, clear, and acne-free complexion.

Healthy, moisturized, radiant, and youthful skin is a goal for many. Achieving this not only involves "beauty from the inside out" through proper nutrition, hydration, rest, emotional well-being, and balanced exercise, but also relies on effective external skin care--where "good microorganisms" play a significant role. 

"Microbiomes are microorganisms that live in our bodies and on our skin. They help maintain skin balance, support overall skin health (such as pH levels, moisture, and skin barrier function), and help prevent infections," explained Associate Professor Dr. Naraporn Somboonna.  She emphasized the growing importance of microbiomes in the health and beauty industry. 

"Balancing the microbiome is key to restoring healthy skin," Assoc. Prof. Dr. Naraporn shared, introducing the idea behind the innovative skincare formula under the "THANARA" brand, developed by "AL-DNA," a startup incubated by CU Innovation Hub/CU Enterprise

Inspiration Behind the Skincare Innovation 

With her expertise in microbiology and portable genetic testing, Assoc. Prof. Dr. Naraporn has created impactful innovations in various fields.  In public health, she developed a three-gene COVID-19 test kit used during the pandemic. In agriculture, she designed an ASFV (African Swine Fever Virus) test kit to help farmers detect infections quickly and conveniently. 

In the food industry, she introduced a Live Total Bacteria and Coliform Detections test kit to identify harmful bacteria in food and beverage production.  Her interest in microbiomes extends to their roles in human and environmental health. She is also a member of the Multi-Omics for Functional Products in Food, Cosmetics, and Animals Research Unit and the Omics Sciences and Bioinformatics Center at Chulalongkorn University. 

Healthy Skin Through Microbiome and 4P-Biotics Technology 

According to Assoc. Prof. Dr. Naraporn, AL-DNA has launched two skincare products, both patented and FDA-certified to ensure user safety:  

  • THANARA Anti-Aging & Sensitive Skin Serum - A concentrated skincare serum that restores microbiome activity, reduces inflammation, increases moisture, and strengthens the skin's balance.
  • THANARA Anti-Aging & All Repair for All Skin Type Skincare SPF50/PA+++ - A sunscreen that combines microbiome support with UV protection to nourish the skin in one step, suitable for all skin types.

"What makes THANARA unique is its use of 4P-Biotics technology--Probiotics, Parabiotics, Prebiotics, and Postbiotics—to help balance the skin's microbiome," Assoc. Prof. Dr. Naraporn explained.  "Moreover, THANARA products are free from potential irritants like alcohol, parabens, and silicone."

AL-DNA: The Future of Health and Beauty 

THANARA products are currently available at the Faculty of Science (Research Division), CU Enterprise, and via online channels. Looking ahead, Assoc. Prof. Dr. Naraporn says that AL-DNA plans to expand its line with additional microbiome-based skincare products, including personalized skin analysis and anti-aging treatments. 

For more information, please contact Assoc. Prof. Dr. Naraporn Somboonna at the Department of Microbiology, Faculty of Science, Chulalongkorn University, or reach out through CU Enterprise and CU Sci Products and Services, or call +6680-440-4509.

View the photo album of this article at https://www.chula.ac.th/en/highlight/232515/

About Chulalongkorn University

"Chulalongkorn University proudly retains its No. 1 position among Thai universities and ranks 132nd in Asia out of more than 2,000 institutions in the THE Asia University Rankings 2025—a testament to the excellence of Thai higher education on the regional stage."

Social Media:

Facebook: https://www.facebook.com/ChulalongkornUniversity
Youtube:
https://www.youtube.com/chulauniversity
Linkedin:
https://www.linkedin.com/school/15101896/

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA

THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA

CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.

The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.

Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.

About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.

For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.

Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com

Investor Relations
ir@fieldmedicalinc.com

 

CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.

The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.

Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.

About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.

For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.

Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com

Investor Relations
ir@fieldmedicalinc.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

Recommended Articles